SOMERSET, N.J., Sept. 29 /PRNewswire-FirstCall/ -- The Franklin Group, a division of Ventiv Health Inc. announced today that it will present at the International Congress of Pharmaceutical Compliance Conference, taking place in St. Tropez, France October 1-3, 2004. Attendees will consist of the top Executives of international Pharmaceutical and Biotech companies from various countries.
Steve A. Tarnoff, Managing Director of The Franklin Group, has been invited to the conference to present on pharmaceutical marketing and compliance challenges with specific focus on the impact of OIG (Office Inspector General) in the pharmaceutical industry. The presentation will address compliance verses profit -- a dilemma facing not just the USA but a number of industrialized countries, as well. Mr. Tarnoff will explain what OIG is, list the components of OIG, illustrate how the U.S. pharmaceutical industry has responded, outline the ways to assess a company’s operational readiness to comply with the OIG guidelines and demonstrate how taking an aggressive approach to formulating compliance can enhance promotional value.
Mr. Tarnoff has been in the pharmaceutical industry for over 25 years and is internationally recognized as an expert and leading authority in the area of U.S. pharmaceutical compliance, specifically in the areas of PDMA, OIG, 21CFR Part 11, HIPAA and state regulations. He is also well respected in the area of pharmaceutical marketing and sales and has been responsible for directing a wide variety of sales and marketing initiatives for leading manufacturers which are governed by PDMA, OIG and collateral federal regulations.
About The Franklin Group
The Franklin Group is a pharmaceutical-specific support organization that possesses both process design and in-depth content expertise across numerous pharmaceutical work processes. This unique combination has allowed The Franklin Group to help clients redesign their organizations to achieve breakthrough performance. Areas where The Franklin Group possesses in-depth expertise include sample accountability, OIG compliance, patient assistance, reimbursement counseling, field force automation, product marketing strategies, sales force optimization, alternate sales channels, and human resources management. For more information on The Franklin Group, please visit http://www.franklingroupinc.com/.
About Ventiv Health
Ventiv Health, Inc. is a leading provider of sales, marketing, and compliance solutions to the world’s largest pharmaceutical companies as well as to emerging and specialty pharmaceutical and biotech organizations. Ventiv has established its leadership position within the industry based on a long history of building and managing sales teams and providing consultative planning and analytics services across multiple therapeutic areas.
The Ventiv delivery model is flexible and client focused, enabling Ventiv to rapidly respond to changing client needs and market conditions across the full spectrum of sales and marketing support, with both integrated and independent programs. These include: Sales and Marketing Teams (Ventiv Sales and Marketing Teams(TM)), Planning and Analytics (Health Products Research(R)), Recruitment (Ventiv Recruitment Services(TM)), Professional Development and Training (Ventiv Professional Development Group(TM)), Marketing Support (PROMOTECH), Data Solutions (Total Data Solutions(TM)), Clinical Support (The Therapeutics Institute(TM)), and Sample Accountability/Patient Assistance Programs (The Franklin Group). Ventiv is a multi-discipline company with a singular focus on providing excellence in customized solutions to meet clients’ sales and marketing objectives.
Ventiv’s approximately 3000 employees support over forty client organizations. For more information on Ventiv Health, visit http://www.ventiv.com/.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health’s performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health Inc.
CONTACT: John Emery, CFO of Ventiv Health, Inc., +1-732-537-4804,investor@ventiv.com; or Felicia Vonella of Lazar Partners Ltd.,+1-212-867-1762, fvonella@lazarpartners.com, for Ventiv Health Inc.
